158 related articles for article (PubMed ID: 35954339)
1. CD109 Is a Critical Determinant of EGFR Expression and Signaling, and Tumorigenicity in Squamous Cell Carcinoma Cells.
Zhou S; Hassan A; Kungyal T; Tabariès S; Luna JLRG; Siegel PM; Philip A
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954339
[TBL] [Abstract][Full Text] [Related]
2. CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.
Mo XT; Leung TH; Tang HW; Siu MK; Wan PK; Chan KK; Cheung AN; Ngan HY
Br J Cancer; 2020 Sep; 123(5):833-843. PubMed ID: 32507856
[TBL] [Abstract][Full Text] [Related]
3. CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro.
Zhou S; da Silva SD; Siegel PM; Philip A
Sci Rep; 2019 Nov; 9(1):16317. PubMed ID: 31695056
[TBL] [Abstract][Full Text] [Related]
4. Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.
Lee KY; Shueng PW; Chou CM; Lin BX; Lin MH; Kuo DY; Tsai IL; Wu SM; Lin CW
Cancer Sci; 2020 May; 111(5):1652-1662. PubMed ID: 32133706
[TBL] [Abstract][Full Text] [Related]
5. CD109 and squamous cell carcinoma.
Qi R; Dong F; Liu Q; Murakumo Y; Liu J
J Transl Med; 2018 Apr; 16(1):88. PubMed ID: 29625613
[TBL] [Abstract][Full Text] [Related]
6. CD109 released from human bone marrow mesenchymal stem cells attenuates TGF-β-induced epithelial to mesenchymal transition and stemness of squamous cell carcinoma.
Zhou S; Cecere R; Philip A
Oncotarget; 2017 Nov; 8(56):95632-95647. PubMed ID: 29221155
[TBL] [Abstract][Full Text] [Related]
7. The Significance of CD109 Expression in Oropharyngeal Squamous Cell Carcinoma.
Tsutsumi S; Momiyama K; Ichinoe M; Kato T; Mogi S; Miyamoto S; Murakumo Y; Yamashita T
Anticancer Res; 2022 Apr; 42(4):2061-2070. PubMed ID: 35347029
[TBL] [Abstract][Full Text] [Related]
8. Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma.
Hagiwara S; Sasaki E; Hasegawa Y; Suzuki H; Nishikawa D; Beppu S; Terada H; Sawabe M; Takahashi M; Hanai N
Cancer Med; 2021 Feb; 10(4):1335-1346. PubMed ID: 33565282
[TBL] [Abstract][Full Text] [Related]
9. CD109 promotes the tumorigenic ability and metastatic motility of pancreatic ductal adenocarcinoma cells.
Hatsuzawa Y; Yamaguchi K; Takanashi T; Sato I; Tamai K; Mochizuki M; Iwai W; Wakui Y; Abue M; Yamamoto K; Yasuda J; Mizuma M; Unno M; Sugamura K
Pancreatology; 2020 Apr; 20(3):493-500. PubMed ID: 32007357
[TBL] [Abstract][Full Text] [Related]
10. Investigation of prognostic significance of CD109 expression in women with vulvar squamous cell carcinoma.
Ozbay PÖ; Ekinci T; Yiǧit S; Yavuzcan A; Uysal S; Soylu F; Cakalagaoglu F
Onco Targets Ther; 2013; 6():621-7. PubMed ID: 23776335
[TBL] [Abstract][Full Text] [Related]
11. CD109 drives pro-tumorigenic cell properties in human non-small cell lung cancer through interaction with desmoglein-2.
Lückstädt W; Rathod M; Möbus L; Bub S; Lucius R; Elsner F; Spindler V; Arnold P
Res Sq; 2024 Mar; ():. PubMed ID: 38562713
[TBL] [Abstract][Full Text] [Related]
12. CD109 expression is upregulated in penile squamous cell carcinoma.
Dong F; Wang J; Xu Y; Cheng Z; Chen X; Wang Y; Liu J
Oncol Lett; 2017 Nov; 14(5):6012-6016. PubMed ID: 29113239
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of CD109 Promotes the Epithelial-to-Mesenchymal Transition and Stemness Properties of Lung Adenocarcinomas via Activation of the Hippo-YAP Signaling.
Lee KY; Kuo TC; Chou CM; Hsu WJ; Lee WC; Dai JZ; Wu SM; Lin CW
Cells; 2020 Dec; 10(1):. PubMed ID: 33375719
[TBL] [Abstract][Full Text] [Related]
14. CD109-mediated degradation of TGF-β receptors and inhibition of TGF-β responses involve regulation of SMAD7 and Smurf2 localization and function.
Bizet AA; Tran-Khanh N; Saksena A; Liu K; Buschmann MD; Philip A
J Cell Biochem; 2012 Jan; 113(1):238-46. PubMed ID: 21898545
[TBL] [Abstract][Full Text] [Related]
15. Suppression of skin tumorigenesis in CD109-deficient mice.
Sunagawa M; Mii S; Enomoto A; Kato T; Murakumo Y; Shiraki Y; Asai N; Asai M; Nagino M; Takahashi M
Oncotarget; 2016 Dec; 7(50):82836-82850. PubMed ID: 27756876
[TBL] [Abstract][Full Text] [Related]
16. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions.
Feng W; Duan X; Liu J; Xiao J; Brown RE
Int J Clin Exp Pathol; 2009; 2(3):249-60. PubMed ID: 19079619
[TBL] [Abstract][Full Text] [Related]
17. Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways.
Zhen L; Fan D; Yi X; Cao X; Chen D; Wang L
Int J Clin Exp Pathol; 2014; 7(10):6438-46. PubMed ID: 25400722
[TBL] [Abstract][Full Text] [Related]
18. High-level expression of CD109 is frequently detected in lung squamous cell carcinomas.
Sato T; Murakumo Y; Hagiwara S; Jijiwa M; Suzuki C; Yatabe Y; Takahashi M
Pathol Int; 2007 Nov; 57(11):719-24. PubMed ID: 17922683
[TBL] [Abstract][Full Text] [Related]
19. Two different protein expression profiles of oral squamous cell carcinoma analyzed by immunoprecipitation high-performance liquid chromatography.
Kim SM; Jeong D; Kim MK; Lee SS; Lee SK
World J Surg Oncol; 2017 Aug; 15(1):151. PubMed ID: 28789700
[TBL] [Abstract][Full Text] [Related]
20. Cell Surface Processing of CD109 by Meprin β Leads to the Release of Soluble Fragments and Reduced Expression on Extracellular Vesicles.
Lückstädt W; Bub S; Koudelka T; Pavlenko E; Peters F; Somasundaram P; Becker-Pauly C; Lucius R; Zunke F; Arnold P
Front Cell Dev Biol; 2021; 9():622390. PubMed ID: 33738281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
